MilliporeSigma, BCM, and the Texas Children's Hospital Center for Vaccine Development are optimizing the production process to advance two COVID-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate, which is expected to enter clinical trials later this year. CoV RBD219-N1 was originally developed to target SARS in 2011-2016, according to the companies.

The new candidates are based on key findings from their ongoing collaboration on a schistosomiasis vaccine. The teams will work together to improve the manufacturing platform for CoV RBD219-N1 and develop an entirely new manufacturing platform for a second COVID-19 vaccine.

MilliporeSigma aims to accelerate the suitability of the candidates for large-scale manufacturing, according to the companies.

Researchers from the Texas Children's Center for Vaccine Development first formed a partnership with MilliporeSigma's process development scientists and biomanufacturing engineers in 2018 to advance vaccine development and production and enhance the response to outbreaks, such as COVID-19.

Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage...

MilliporeSigma expands viral and gene therapy capacity
MilliporeSigma is expanding its BioReliance viral and gene therapy service offering with a second commercial manufacturing facility in Carlsbad, CA. The...